Withdrawn study aimed to counteract antibodies blocking hypophosphatasia drug
NCT ID NCT06015750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a combination of immunosuppressive drugs (methotrexate, rituximab, bortezomib, IVIg, and folic acid) in people with hypophosphatasia whose bodies had stopped responding to asfotase alfa due to antibodies. The goal was to see if suppressing the immune system could restore the drug's effectiveness. However, the trial was withdrawn before any participants were enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- methotrexate, rituximab, bortezomib, IVIg, folic acid
- What this could lead to
- If successful, this approach could help restore the effectiveness of asfotase alfa in patients whose bodies have developed antibodies against it.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data were collected. Immunosuppressive therapies carry risks of infection and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Genetic deep dive uncovers hidden clues in rare bone disease
- Scientists launch largest-ever natural history study for rare bone disease hypophosphatasia
- Could your body fight back against this rare disease drug?
- New study tracks rare bone disease to unlock clues for better diagnosis
- New study aims to cut diagnostic delays for rare bone disease